Par injicējamu ARV-shēmu HIV ārstēšanai
Apskatīt komentārus (0)
10.01.2016
Pašlaik tiek veikta klīnisko izmēģinājumu trešā fāze un kombinācija potenciāli var kļūt par pirmo pilnībā injicējamo shēmu HIV infekcijas ārstēšanai. Ja tiks pierādīta tās efektivitāte, pacienti, kas dzīvo ar HIV, gūs iespēju vienu reizi 4 vai 8 nedēļās izmantot minēto shēmu, tā vietā, lai katru dienu lietotu standarta tablešu kombināciju vismaz no trīs preparātiem.
************************
Source: «Janssen to Progress Collaboration with ViiV Healthcare to Develop the First Long Acting Two Drug Injectable Regimen for Treatment of HIV Infection» | http://www.prnewswire.com/news-releases/janssen-to-progress-collaboration-with-viiv-healthcare-to-develop-the-first-long-acting-two-drug-injectable-regimen-for-treatment-of-hiv-infection-564497381.html |
CORK, Ireland, January 7, 2016 /PRNewswire/ --
Results from ongoing phase IIb Week 32 study show that if successfully developed and approved, people living with HIV could potentially maintain viral suppression
Janssen Sciences Ireland UC (Janssen), today formalized its collaboration with ViiV Healthcare on phase III development and commercialization of a two drug regimen of two long acting, all-injectable formulations of rilpivirine (a non-nucleoside reverse transcriptase inhibitor by Janssen) and cabotegravir (ViiV Healthcare).
<... At week 32, in an ongoing phase IIb study (LATTE 2, NCT02120352), the investigational long acting, all-injectable combination regimen, given every 4 or 8 weeks, showed comparable efficacy to a daily oral regimen of three HIV medicines (investigational cabotegravir and two nucleoside reverse transcriptase inhibitors (NRTIs)). If successfully developed and approved by regulatory authorities, people living with HIV who are virologically suppressed could be offered an alternative option to the standard oral daily regimen* of three drug therapy.
"While we work toward our long-term goal of developing a preventative HIV vaccine, we are excited to be able to continue to support people living with HIV through innovative improvements," said Wim Parys, Head of R&D, Global Public Health, Janssen. "Through this collaboration, we have the potential to develop the first long acting, all-injectable two drug regimen as an innovative option for HIV maintenance therapy." ...>
Atpakaļ